Evolveimmune Therapeutics Inc. has unveiled EVOLVE-205, a new 2:1 T-cell engager targeting CD20 with integrated affinity-tuned CD3 and CD2 agonists to promote anti-B-cell immunity. BioWorld Science ...

The Raman and Athar team's study uncovered that the lymphocyte cell surface protein CD2 is expressed at elevated levels on T lymphocytes and innate lymphocytes, including natural killer cells (NK ...